Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer.
Nicholas D JamesAyesha AliAnn PopeAmisha DesaiDaniel FordRobert StevensonAnjali ZarkarSarah J Pirrienull nullPublished in: BJUI compass (2022)
Due to the low number of patients recruited, meaningful comparisons could not be made. However, toxicity was in line with known outcomes for these agents, demonstrating it is feasible and safe to deliver chemotherapy to men relapsing with CRPC after upfront chemotherapy.
Keyphrases
- prostate cancer
- locally advanced
- end stage renal disease
- multiple sclerosis
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- small cell lung cancer
- chronic kidney disease
- oxidative stress
- radical prostatectomy
- peritoneal dialysis
- rectal cancer
- radiation therapy
- patient reported outcomes
- rheumatoid arthritis
- skeletal muscle